129 related articles for article (PubMed ID: 8159008)
1. How does negative clinical evaluation of ovarian carcinoma after full course of chemotherapy correlate with second-look laparotomy findings?
Zorlu CG; Cobanoglu O; Caglar T; Ergun Y; Kuscu E; Alaybeyoglu T
J Surg Oncol; 1994 Apr; 55(4):255-8. PubMed ID: 8159008
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study.
Sato N; Akahira J; Kitamura T; Aoki M; Yoshinaga K; Okamura C; Utsunomiya H; Shimizu T; Niikura H; Ito K; Okamura K; Yaegashi N
Int J Clin Oncol; 2003 Feb; 8(1):40-4. PubMed ID: 12601541
[TBL] [Abstract][Full Text] [Related]
3. Place of second-look laparotomy after 18 courses of chemotherapy in epithelial ovarian cancer.
Ngan HY; Wong LC; Ma HK
Aust N Z J Obstet Gynaecol; 1989 Feb; 29(1):52-4. PubMed ID: 2562603
[TBL] [Abstract][Full Text] [Related]
4. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
5. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: a preliminary report.
Piver MS; Malfetano J; Baker TR; Lele SB; Marchetti DL
Gynecol Oncol; 1989 Oct; 35(1):69-72. PubMed ID: 2792905
[TBL] [Abstract][Full Text] [Related]
7. The role of second-look laparotomy in the management of patients with stage II, III and IV ovarian cancers following chemotherapy with cisplatin, adriamycin and cyclophosphamide.
Kirwan PH; Naftalin NJ; Khanna S; Aukett RJ
Br J Obstet Gynaecol; 1986 Jun; 93(6):629-33. PubMed ID: 3730331
[TBL] [Abstract][Full Text] [Related]
8. High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer.
Hunter RE; Griffin TW; Stevens S; Roman LD; Bokhari F; Reale FR; Tak WK; Fitzgerald TJ; Dillon MB; Rose PG
Cancer; 1991 Nov; 68(9):1890-4. PubMed ID: 1655227
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
10. Negative second-look laparotomy does not preclude recurrence in stage I ovarian carcinoma of any histological variety.
Schneider J; Centeno MM; Montoya F; Rodriguez-Escudero FJ
Eur J Gynaecol Oncol; 1993; 14(1):36-9. PubMed ID: 8472729
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
Omura GA; Bundy BN; Berek JS; Curry S; Delgado G; Mortel R
J Clin Oncol; 1989 Apr; 7(4):457-65. PubMed ID: 2926470
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing period of time between negative second-look laparotomy and ovarian carcinoma recurrence. Multicenter study in Poland.
Markowska J; Wilkoszarska J; Emerich J; Debniak J; Popiela A; Pańszczak M; Kornafel J; Rossochacka B; Fisher Z; Goluda M; Małecki P
Eur J Gynaecol Oncol; 2000; 21(2):164-7. PubMed ID: 10843477
[TBL] [Abstract][Full Text] [Related]
13. Second-look laparotomy after chemotherapy in the management of ovarian malignancy.
Smirz LR; Stehman FB; Ulbright TM; Sutton GP; Ehrlich CE
Am J Obstet Gynecol; 1985 Jul; 152(6 Pt 1):661-8. PubMed ID: 4040706
[TBL] [Abstract][Full Text] [Related]
14. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
15. Second-look laparotomy; factors affecting the results and the prognosis.
Ozalp S; Yalcin OT; Dundar E; Hassa H; Yildirim A; Okur A
Eur J Gynaecol Oncol; 1999; 20(5-6):398-402. PubMed ID: 10609505
[TBL] [Abstract][Full Text] [Related]
16. Relationship between peritoneal washing cytology through implantable port system (IPS-cytology) and second-look laparotomy in ovarian cancer patients with unmeasurable residual diseases.
Fujiwara K; Yamauchi H; Yoshida T; Suzuki S; Oda T; Kohno I
Gynecol Oncol; 1998 Aug; 70(2):231-5. PubMed ID: 9740696
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in ovarian carcinoma. Results after second-look laparotomy.
Schneider J; Martin M; Erasun F; Matia JC; Rodriguez-Escudero FJ
Oncology; 1990; 47(2):109-11. PubMed ID: 2314822
[TBL] [Abstract][Full Text] [Related]
18. Clinical remission criteria for epithelial carcinoma of the ovary.
Morikawa Y; Kawai M; Kano T; Kikkawa F; Oguchi H; Nakashima N; Ishizuka T; Furuhashi Y; Hattori SE; Kuzuya K
Gynecol Oncol; 1993 Mar; 48(3):342-8. PubMed ID: 7681806
[TBL] [Abstract][Full Text] [Related]
19. [Studies of second-look operations (SLO) in ovarian cancer].
Yuzawa H
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1310-6. PubMed ID: 2658822
[TBL] [Abstract][Full Text] [Related]
20. Second-look laparotomy in ovarian carcinoma patients after 8 and after 12 courses of cisplatin-based chemotherapy.
Menczer J; Ben-Baruch G; Modan M; Brenner H
Gynecol Obstet Invest; 1989; 27(2):102-4. PubMed ID: 2731767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]